AKKARAJU SRINIVAS — SEC Form 4 filings
SEC reporting owner CIK 1253170. 45 Form 4 filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers all 45 filings on record, filed 2024-02-14 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 41 legs across 18 filings — 7,508,189 shares, $111,799,630 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 2 filings — 1,271,844 shares, $35,399,701 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: purchase of 1,562,500 shares @ $16.00 ($25,000,000) in ALUMIS INC., filed 2024-08-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALUMIS INC. (ALMS) | Director | 14 | 23 legs · 4,722,999 sh · $56,273,055 | 2 legs · 96,131 sh · $1,014,028 | 8 |
| Scholar Rock Holding Corp (SRRK) | Director | 6 | 9 legs · 530,038 sh · $19,988,986 | 3 legs · 1,175,713 sh · $34,385,672 | 8 |
| Mineralys Therapeutics, Inc. (MLYS) | Director, 10% owner | 6 | 2 legs · 1,188,235 sh · $23,099,992 | — | 5 |
| Kalaris Therapeutics, Inc. (KLRS) | Director | 6 | 2 legs · 724,147 sh · $6,179,975 | — | 7 |
| CARGO Therapeutics, Inc. (CRGX) | 10% owner | 1 | 1 leg · 294,000 sh · $4,998,000 | — | — |
| Neurogene Inc. (NGNE) | 10% owner | 1 | 4 legs · 48,770 sh · $1,259,623 | — | — |
| vTv Therapeutics Inc. (VTVT) | Director | 8 | — | — | 14 |
| Syros Pharmaceuticals, Inc. (SYRS) | Director | 3 | — | — | 6 |
Form 4 filings — AKKARAJU SRINIVAS
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 220,070 @ $11.17 · Purchase (P): 220,070 @ $11.17 · Sale (S): 48,066 @ $10.55 · Sale (S): 48,065 @ $10.55 · Purchase (P): 273,291 @ $10.63 · Purchase (P): 273,290 @ $10.63 | EDGAR |
| 2026-07-02 | 4 | ALUMIS INC. (ALMS) | Grant/award (A): 3,553 @ $0 · Grant/award (A): 15,528 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | vTv Therapeutics Inc. (VTVT) | Grant/award (A): 6,000 (derivative) @ $35.08 | EDGAR |
| 2026-06-08 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 6,839 @ $0 · Grant/award (A): 4,310 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kalaris Therapeutics, Inc. (KLRS) | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Kalaris Therapeutics, Inc. (KLRS) jointly with Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC | Purchase (P): 244,300 @ $4.83 · Other (J): 66,906 @ $0 · Other (J): 14,937 @ $0 · Other (J): 4,471 @ $0 | EDGAR |
| 2026-02-20 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Kalaris Therapeutics, Inc. (KLRS) jointly with Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC | Purchase (P): 479,847 @ $10.42 | EDGAR |
| 2026-01-13 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 588,235 @ $17 | EDGAR |
| 2025-12-22 | 4 | Kalaris Therapeutics, Inc. (KLRS) jointly with Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC | Grant/award (A): 1,500,000 @ $10 | EDGAR |
| 2025-12-16 | 4 | Scholar Rock Holding Corp (SRRK) | Purchase (P): 12,796 @ $39.31 · Purchase (P): 12,400 @ $40.18 · Purchase (P): 4,403 @ $40.97 · Option exercise/expiry (X): 1,064,804 @ $7.35 · Option exercise/expiry (X): 1,064,804 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 64,969 @ $8.95 · Purchase (P): 70,028 @ $10.01 · Purchase (P): 51,380 @ $10.73 | EDGAR |
| 2025-12-04 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 96,000 @ $7.55 · Purchase (P): 100,000 @ $7.75 · Purchase (P): 66,027 @ $8.18 | EDGAR |
| 2025-12-01 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 48,537 @ $7.64 · Purchase (P): 38,702 @ $7.64 · Purchase (P): 86,350 @ $7.46 | EDGAR |
| 2025-11-24 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 125,743 @ $7.20 | EDGAR |
| 2025-11-19 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 914 @ $5.51 · Purchase (P): 102,652 @ $6.05 · Purchase (P): 137,772 @ $6.56 | EDGAR |
| 2025-11-17 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 276,179 @ $5.25 | EDGAR |
| 2025-10-07 | 4 | Scholar Rock Holding Corp (SRRK) | Purchase (P): 11,011 @ $35.61 · Purchase (P): 56,703 @ $36.74 · Purchase (P): 319,700 @ $37.42 · Purchase (P): 18,414 @ $37.89 · Purchase (P): 80,863 @ $38.68 · Purchase (P): 13,748 @ $39.52 | EDGAR |
| 2025-09-25 | 4 | vTv Therapeutics Inc. (VTVT) | Grant/award (A): 106,000 @ $15.27 · Grant/award (A): 877,214 (derivative) · Grant/award (A): 983,214 (derivative) | EDGAR |
| 2025-09-08 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Purchase (P): 588,235 @ $25.50 | EDGAR |
| 2025-09-05 | 4 | vTv Therapeutics Inc. (VTVT) | Grant/award (A): 655,523 (derivative) · Grant/award (A): 655,523 (derivative) | EDGAR |
| 2025-08-01 | 4 | ALUMIS INC. (ALMS) | Grant/award (A): 49,800 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | vTv Therapeutics Inc. (VTVT) | Grant/award (A): 4,000 (derivative) @ $16.59 | EDGAR |
| 2025-05-23 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 7,632 @ $0 · Grant/award (A): 9,206 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | ALUMIS INC. (ALMS) | Grant/award (A): 1,214,582 | EDGAR |
| 2025-05-06 | 4 | ALUMIS INC. (ALMS) | Purchase (P): 159,920 @ $4.55 · Purchase (P): 138,368 @ $4.58 · Purchase (P): 22,002 @ $5.27 | EDGAR |
| 2025-04-24 | 4 | vTv Therapeutics Inc. (VTVT) | Grant/award (A): 2,250 (derivative) @ $17.22 · Grant/award (A): 983 (derivative) @ $17.22 | EDGAR |
| 2025-04-11 | 4 | Kalaris Therapeutics, Inc. (KLRS) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Kalaris Therapeutics, Inc. (KLRS) | Grant/award (A): 11,444,503 | EDGAR |
| 2025-03-17 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Purchase (P): 600,000 @ $13.50 | EDGAR |
| 2025-02-24 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with Samsara BioCapital, L.P. | Grant/award (A): 32,900 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | vTv Therapeutics Inc. (VTVT) | Disposition to issuer (D): 58,836 · Grant/award (A): 58,885 (derivative) | EDGAR |
| 2024-11-27 | 4 | Neurogene Inc. (NGNE) jointly with Samsara BioCapital GP, LLC, Samsara BioCapital, L.P. | Purchase (P): 20,748 @ $24.91 · Purchase (P): 10,803 @ $26.01 · Purchase (P): 15,219 @ $26.73 · Purchase (P): 2,000 @ $27.50 | EDGAR |
| 2024-10-07 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 510,000 @ $27.50 · Sale (S): 510,000 @ $30 · Sale (S): 155,713 @ $32.50 | EDGAR |
| 2024-09-18 | 4 | Syros Pharmaceuticals, Inc. (SYRS) | Option exercise (M): 2,667 · Option exercise (M): 2,667 (derivative) @ $0 | EDGAR |
| 2024-08-27 | 4/A | ALUMIS INC. (ALMS) | Purchase (P): 1,562,500 @ $16 | EDGAR |
| 2024-07-01 | 4 | ALUMIS INC. (ALMS) | Conversion (C): 1,703,998 · Disposition to issuer (D): 1,703,998 · Grant/award (A): 1,703,998 · Conversion (C): 1,703,998 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 13,500 @ $0 · Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | vTv Therapeutics Inc. (VTVT) | Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Syros Pharmaceuticals, Inc. (SYRS) | Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Syros Pharmaceuticals, Inc. (SYRS) | Option exercise (M): 4,000 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | CARGO Therapeutics, Inc. (CRGX) jointly with Samsara BioCapital GP, LLC, Samsara BioCapital, L.P. | Purchase (P): 294,000 @ $17 | EDGAR |
| 2024-05-23 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with Samsara BioCapital, L.P. | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | vTv Therapeutics Inc. (VTVT) | Grant/award (A): 224,732 @ $11.81 · Grant/award (A): 833,693 (derivative) @ $11.80 | EDGAR |
| 2024-02-14 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 555,555 @ $13.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1253170 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →